Skip subpage navigation
The Food & Drug Administration's Center for Biologics Evaluation and Research regulates biological products for human use under applicable federal laws, including the Public Health Service Act and the Federal Food, Drug and Cosmetic Act. CBER protects and advances the public health by ensuring that biological products are safe and effective and available to those who need them. CBER also provides the public with information to promote the safe and appropriate use of biological products. It also approves the product labeling (package insert).
Please click below for the latest package inserts for licensed vaccines:
| Chikungunya |
Date |
IXCHIQ
|
November 2023 |
| Human Papillomavirus |
Date |
Gardasil 9
|
March 14, 2024 |
| Japanese Encephalitis |
Date |
Ixiaro
|
Oct. 4, 2018 |
| MPOX/Smallpox |
Date |
JYNNEOS
|
Nov. 25, 2024 |
| Tetanus-Diphtheria-Pertussis |
Date |
Adacel
|
May 11, 2023 |
Boostrix
|
Oct. 27, 2023 |
Daptacel
|
July 21, 2022 |
Diphtheria and Tetanus Toxoid Adsorbed
|
Dec. 20, 2018 |
Infanrix
|
Oct. 27, 2023 |
Kinrix
|
Oct. 27, 2023
|
Pediarix
|
April 26, 2023
|
Pentacel
|
Oct. 21, 2022 |
Quadracel
|
July 21, 2022
|
Tenivac
|
Dec. 16, 2022 |
Vaxelis
|
April 12, 2023 |
| Tick-Borne Encephalitis |
Date |
TICOVAC
|
July 2023 |
| Yellow Fever |
Date |
YF-VAX
|
Aug. 6, 2019 |
You are leaving Health.mil
The appearance of hyperlinks does not constitute endorsement by the Department of Defense of non-U.S. Government sites or the information, products, or services contained therein. Although the Defense Health Agency may or may not use these sites as additional distribution channels for Department of Defense information, it does not exercise editorial control over all of the information that you may find at these locations. Such links are provided consistent with the stated purpose of this website.
You are leaving Health.mil
View the external links disclaimer.
Last Updated: March 13, 2025